Literature DB >> 23007270

Haematological cancer: Hit the lymphoma, JAK.

Rebecca Kirk.   

Abstract

Entities:  

Year:  2012        PMID： 23007270     DOI： 10.1038/nrclinonc.2012.174

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

Review 1.  From drug discovery to biomarker-driven clinical trials in lymphoma.

Authors:  Anas Younes; Donald A Berry
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

2.  Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

Authors:  Anas Younes; Jorge Romaguera; Michelle Fanale; Peter McLaughlin; Frederick Hagemeister; Amanda Copeland; Sattva Neelapu; Larry Kwak; Jatin Shah; Silvana de Castro Faria; Stefan Hart; Jeanette Wood; Ramesh Jayaraman; Kantharaj Ethirajulu; Joy Zhu
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544
  2 in total
  2 in total

1.  c-Abl activates janus kinase 2 in normal hematopoietic cells.

Authors:  Wenjing Tao; Xiaohong Leng; Sandip N Chakraborty; Helen Ma; Ralph B Arlinghaus
Journal:  J Biol Chem       Date:  2014-06-12       Impact factor: 5.157

Review 2.  STAT3 inhibitors: finding a home in lymphoma and leukemia.

Authors:  Javier Munoz; Navjot Dhillon; Filip Janku; Stephanie S Watowich; David S Hong
Journal:  Oncologist       Date:  2014-04-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.